The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...